Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Discover why Novo Nordisk A/S' undervalued shares present a buying opportunity, with strong sales growth, profitability, and ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Having dedicated the book to his late father Dr. Michael Mosley, a much-loved fixture on our screens and airwaves whose work ...

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

GLP-1 drugs like Wegovy and Ozempic are designed to treat type 2 diabetes, but are widely known for their effect on weight ...

Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...